Tagrisso (osimertinib)

pCPA File Number: 21092

Negotiation Status:

Concluded with an LOI

Indication(s):

first-line treatment of locally advanced or metastatic non-small cell cell lung cancer (NSCLC)

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CADTH Project Number:

pCODR 10137

pCPA Engagement Letter Issued:

2019-03-14

Negotiation Process Concluded:

2019-11-19